Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups. Oncology Practice Management (OPM) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities.
This new feature in OPM aims to provide ongoing lists of US-based phase 2 or 3 clinical trials that are actively recruiting. Healthcare practitioners may use this listing in discussions with their patients to encourage enrollment. As the National Comprehensive Cancer Network has stated, “The best management of any cancer patient is in a clinical trial.”
These clinical trial listings can be found at www.ClinicalTrials.gov.
- A Phase 2 Study to Evaluate the Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies
- ClinicalTrials.gov Identifier: NCT04728893
- Sponsor: Merck Sharp & Dohme LLC
- Compound/Drug Name: MK-1026-003
- Conditions: Lymphoid malignancies: leukemia, non-Hodgkin lymphoma, B-cell lymphoma, chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma
- Phase: Phase 2
- Study Type: Interventional (clinical trial)
- Locations: Argentina, Australia, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Romania, South Korea, Spain, Switzerland, Turkey, Ukraine, United Kingdom, USA
- A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)
- ClinicalTrials.gov Identifier: NCT06136559
- Sponsor: Merck Sharp & Dohme LLC
- Compound/Drug Name: MK-1026-011
- Conditions: Lymphoid malignancies: leukemia, non-Hodgkin lymphoma, chronic lymphocytic leukemia
- Phase: Phase 3
- Locations: Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Germany, Greece, Hong Kong, Israel, Japan, Malaysia, Mexico, New Zealand, Norway, Peru, Poland, Portugal, South Africa, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, USA
- A Phase 2/3 Multicenter, Open-Label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)
- ClinicalTrials.gov Identifier: NCT05139017
- Sponsor: Merck Sharp & Dohme LLC
- Condition: Diffuse large B-cell lymphoma
- Study Type: Interventional (clinical trial)
- Locations: Australia, Canada, China, Costa Rica, France, Guatemala, Hong Kong, Israel, Italy, Poland, South Korea, Thailand, Turkey, Ukraine, United Kingdom, USA
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician’s Choice Chemotherapy in PD-(L)1-Refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
- ClinicalTrials.gov Identifier: NCT05508867
- Sponsor: Merck Sharp & Dohme LLC
- Condition: Hodgkin lymphoma
- Locations: Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Israel, Mexico, Poland, South Korea, Spain, Sweden, Switzerland, Turkey, United Kingdom, USA
- A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Hyaluronidase in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
- ClinicalTrials.gov Identifier: NCT06504394
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Hodgkin lymphoma, B-cell lymphoma
- Locations: Chile, South Korea, New Zealand, Poland, Spain, USA
- A Multicenter, Open-Label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-Cell Malignancies
- ClinicalTrials.gov Identifier: NCT05458297
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-Hodgkin lymphoma, B-cell lymphoma (follicular lymphoma, mantle cell lymphoma)
- Locations: Brazil, Canada, Chile, China, Czech Republic, Estonia, Germany, Ireland, Israel, Italy, Japan, Peru, Poland, Portugal, Singapore, South Korea, Spain, Sweden, Turkey, United Kingdom, USA
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
- ClinicalTrials.gov Identifier: NCT06079879
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Myeloid malignancies: thrombocythemia
- Locations: Argentina, Australia, Canada, China, Colombia, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Poland, Portugal, South Korea, Spain, Sweden, Taiwan, Turkey, United Kingdom, USA
- A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naive Essential Thrombocythemia Participants
- ClinicalTrials.gov Identifier: NCT06456346
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Myeloid malignancies: thrombocythemia
- Locations: Argentina, Australia, Austria, Chile, Colombia, Denmark, France, Hong Kong, Israel, Italy, Japan, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, USA